Univariate analysis of the prognostic factors
| Variable | Hazard ratio (95% CI) | p value |
|---|---|---|
| Diagnosis, PPH v secondary PH | 1.22 (0.97 to 1.53) | 0.096 |
| Treatment, PT vCT | 0.98 (0.79 to 1.21) | 0.816 |
| Vasodilator response | 0.93 (0.73 to 1.18) | 0.555 |
| NYHA (class III and IV) | 1.52 (1.11 to 2.09) | 0.009 |
| Sex (male) | 1.07 (0.87 to 1.32) | 0.494 |
| Age (/year increase) | 1.00 (0.98 to 1.02) | 0.900 |
| Svo 2 (/% increase) | 0.97 (0.95 to 0.98) | < 0.001 |
| CO (/litre/min increase) | 0.77 (0.62 to 0.97) | 0.016 |
| CI (/litre/min/m2) | 0.72 (0.49 to 1.06) | 0.082 |
| mRAP (/mm Hg increase) | 1.04 (1.01 to 1.07) | 0.018 |
| PVR (Wood units) | 1.02 (1.00 to 1.04) | 0.047 |
| mPAP (/mm Hg increase) | 1.00 (0.99 to 1.01) | 0.763 |
Hazard ratio analysis using a univariate analysis. The p value is derived from the likelihood ratio test.
PT, prostaglandin treatment; CT, conventional treatment; CI, cardiac index; CO, cardiac output; mPAP, mean pulmonary artery pressure; mRAP mean right atrial pressure; NYHA, New York Heart Association grade; PPH, primary pulmonary hypertension; PVR, pulmonary vascular resistance; secondary PH, pulmonary hypertension secondary to systemic disease and thromboembolic disease; Svo 2, mixed venous oxygen saturation.